On Tuesday, ARM Holdings plc (ADR)(NASDAQ:ARMH)’s shares declined -2.69% to $43.03.
New wearable technologies, counting a malaria alert bracelet for infants, a water purification band, and an ear-worn pneumonia monitor, are among the 10 ideas selected for the final stage of the Wearables for Good design challenge. Launched in May 2015 by partners UNICEF, ARM and frog, the objective was to create the most globally inclusive design competition ever. Less than three months later, teams and individuals from 46 countries, covering six continents, had entered with 250 design ideas presented to the judges.
The 10 shortlisted teams comprise of innovative designers, engineers and technologists who have all created remarkable new wearable and sensor-based devices capable of assisting the world’s most vulnerable people. This is a departure from the current mainstream wearables market, which is mainly focused on lifestyle devices for the developed world. The Wearables for Good design challenge expands that focus, showing how wearables can save lives by tackling maternal and child health issues in the most difficult physical and energy-constrained environments.
ARM Holdings plc, together with its auxiliaries, designs microprocessors, physical intellectual property (IP), and related technology and software. The company also sells development tools that enhance the performance of embedded applications. Its products comprise microprocessor cores that comprise of specific functions, such as video, graphics, and display technology IP; and physical IP components for the design and manufacture of integrated circuits, which comprise embedded memory, standard cell, and input/output components.
MiMedx Group Inc(NASDAQ:MDXG)’s shares dropped -3.81% to $10.35.
MiMedx Group, Inc. (MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, declared recently the publication of the Company’s Primer “Amniotic Membrane Regenerative Healing” and its unveiling at the Symposium on Advanced Wound Care (SAWC) Fall 2015 meeting in Las Vegas, Nevada from September 26th - 28th, 2015.
The MiMedx Primer is being offered to healthcare professionals to assist educate and bring discipline to the development and use of the promising amniotic tissue technology. “We believe our Primer should clarify numerous issues in terms of the healing process, the modes of action of amniotic membrane allografts, and the basis for demonstrating clinical safety and efficacy for these allografts. We trust that clinicians will appreciate the education this book will provide,” said Parker H. “Pete” Petit, Chairman and CEO.
MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix. The companys AmnioFix and EpiFix are tissue technologies processed from human amniotic membrane derived from donated placentas.
At the end of Tuesday’s trade, Merge Healthcare Inc.(NASDAQ:MRGE)‘s shares surged dipped XXX% to $7.10.
Merge Healthcare Incorporated (MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, reached a contract to provide its Merge Hemo(TM) solution to Baptist Health System of Birmingham, Alabama.
Baptist Health System was seeking a technology solution that would streamline its workflows and monitor patients throughout their entire cardiac procedure. Using Merge Hemo(TM), the cardiology teams at Princeton Baptist Medical Center, Shelby Baptist Medical Center and Walker Baptist Medical Center will be able to leverage a centralized, web-based system for report generation and distribution.
Merge Healthcare Incorporated develops software solutions that facilitate the sharing of images to create an electronic healthcare experience for patients and physicians worldwide. It operates in two segments, Merge Healthcare and Merge DNA.
Consolidated Edison, Inc.(NYSE:ED), ended its Tuesday’s trading session with -0.03% loss, and closed at $65.01.
ConEdison Development is an unregulated partner of Merged Edison, Inc. [NYSE: ED], ConEdison Development (CED), a New York State-based developer and operator of large-scale renewable energy projects, has attained a 50 percent interest in the 240 MW AC (335 MW DC) Panoche Valley Solar Farm in San Benito County, California from Renewable Energy Trust Capital Inc. (RET Capital).
CED will provide construction administration, operations and maintenance, and asset administration for the project. RET Capital, one of the country’s leading finance and asset administration platforms for the renewable energy industry, had been an early investor and sole owner of the project, and the companies now hold equal shares of ownership.
CED will provide construction administration, operations and maintenance, and asset administration for the project. RET Capital, one of the country’s leading finance and asset administration platforms for the renewable energy industry, had been an early investor and sole owner of the project, and the companies now hold equal shares of ownership.
With about 1.1 million panels planned for the Panoche Valley installation, construction is planned to commence by the end of the year.
The project site is situated about 140 miles southeast of San Francisco.
Merged Edison, Inc., through its auxiliaries, engages in regulated electric, gas, and steam delivery businesses in the United States. It offers electric services to about 3.4 million customers in New York City and Westchester County; gas to about 1.1 million customers in Manhattan, the Bronx, and parts of Queens and Westchester County; and steam to about 1,700 customers in parts of Manhattan.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
